替吉奥联合奥沙利铂与替吉奥联合多西他赛治疗晚期胃癌的临床观察

目的观察国产替吉奥联合奥沙利铂与替吉奥联合多西他赛方案治疗晚期胃癌的近期疗效和毒副反应。方法43例晚期胃癌患者，替吉奥联合奥沙利铂组（OXA组）26例，具体为：替吉奥胶囊：40mg／m2，口服，2次／d，第1～14天，3w为1周期；OXA：130mg／m2，静滴，第1天，3w为1周期。替吉奥联合多西他赛组（TXT组）17例，具体为：替吉奥胶囊用法同OXA组；TxT：60mg／m2，静滴，第1天，3w为1周期。治疗2周期后评价近期疗效、毒副反应和生活质量。结果43例患者均可评估毒副反应，42例患者可评价近期疗效，OXA组与TXT组有效率分别为57．7％和31．3％，差异无统计学意义（P=0．096）。TXT组自细胞减少（94．1％）、口腔炎（35．3％）和便秘（76．5％）的总发生率明显高于OXA组（73．1％、3．8％、38．5％），差异有统计学意义（P=0．019，0．006，0．015）；OXA组的神经毒性发生率（53．8％）显著高于TXT组（17．6％），差异有统计学意义（P〈0．05）。结论替吉奥联合奥沙利铂治疗晚期胃癌与替吉奥联合多西他赛相比，疗效相当，毒副反应TXT组略高于OXA组。

Clinical Observation for Gimeracil and Oteracil Porassium Capsules Combined with Oxaliplatin or Taxotere in Patients with Advanced Gastric Cancer

Objective combination with oxaliplatin three patients with advanced capsules in combination with To investigate the efficacy and safety of gimeracil and oteracil porassium capsules in （OXA） or taxotere （TXT） in treatment of advanced gastric cancer. Methods Forty gastric cancer were divided into two groups： Group gimeraeil and oteracil porassium OXA （group OXA） with 26 patients （gimeracil and oteracil porassium capsules： 40 mg/m2 ,po, bid,d1-d14; OXA： 130 mg/m2, ivgtt, dl, three weeks was a cycle）; Group gimeracil and oteracil porassium capsules in combination with TXT （group TXT） with 17 patients （gimeracil and oteracil porassium capsules： 40 mg/m2 , po, bid, d1-d14; TXT： 60 mg/m2 , ivgtt, d1, three weeks was a cycle）. Results Adverse effects could be evaluated in all cases, response rates could be evaluated in 42 cases. In group OXA and group TXT, the response rates were 57. 7% and 31. 3% （P = 0. 096）. Group TXT had a significant higher incidence in leucopenia（94.1%）, stomatitis（35.3%） and constipation（76.5% ） than group OXA （73.1% ,3.8% ,38.5%） （P= 0. 019,0. 006,0. 015）. Group OXA had significantly more occurrence rate in neurotoxicity than group TXT （53.8% vs 17.6% ,P=0. 018）. Conclusion The response rates of Gimeracil and oteracil porassium capsules combined with oxaliplatin regimen or taxotere regimen had no significant difference, and group TXT had higher adverse effects than group OXA.